Changes in the expression of genes associated with intraneuronal amyloid-β and tau in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 19, Issue 1, 2010, Pages 97-109

  Fujimura, Robert K ^a   Reiner, Teresita ^a   Ma, Fangchao ^a,e   Phillips, Virginia ^b   De Las Pozas, Alicia ^a   Dickson, Dennis W ^b   Roos, Bernard A ^a,c,d   Howard, Guy A ^a,c   Perez Stable, Carlos ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Stein Gerontological Institute   (United States)

^e ILLINOIS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Amyloid ; Brain derived neurotrophic factor (BDNF); Cytochrome C oxidase subunit II (COX2); Double immunofluorescence; Dynamin 1 (DYN); Phospho tau; QRT PCR

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYTOCHROME C OXIDASE; DYNAMIN I; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOREACTIVITY; LASER MICRODISSECTION; MEMORY; MITOCHONDRION; NERVE CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SYNAPSE;

EID: 75149146111     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1216     Document Type: Article

References (52)

1. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid-peptide in the brain and cognitive decline. JAMA 283, 1571-1577.
2. Selkoe DJ, Schenk D (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann Rev Pharmacol Toxicol 43, 545-584.
3. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
4. Mahley RW,Weisgraber KH, Huang Y (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 103, 5644-5651.
5. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
6. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal A? causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688.
7. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid- protein specifically disrupt cognitive function. Nature Neurosci 8, 79-84.
8. Flood DG, Coleman PD (1990) Hippocampal plasticity in normal aging and decreased plasticity in Alzheimer's disease. Prog Brain Res 83, 435-443.
9. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 573-580.
10. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16, 285-298.
11. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56, 933-944.
12. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DWJr, Morris JC (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56, 127-129.
13. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
14. Yao PJ (2004) Synaptic frailty and clathrin-mediated synaptic vesicle trafficking in Alzheimer's disease. Trends Neurosci 27, 24-29.
15. Kelly BL, Vassar R, Ferreira A (2005) Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons: a potential mechanism for early cognitive decline in Alzheimer's disease. J Biol Chem 280, 31746-31753.
16. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H,Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, SmithMA(2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767.
17. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, Jung Y, Yau V, Searles R, Mori M, Quinn J (2004) Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 13, 1225-1240.
18. Takuma K, Yan SS, Stern DM, Yamada K (2005) Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease. J Pharmacol Sci 97, 312-316.
19. Reddy PH (2006) Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem 96, 1-13.
20. Keating DJ (2008) Mitochondrial dysfunction, oxidative stress, regulation of exocytosis and their relevance to neurodegenerative diseases. J Neurochem 104, 298-305.
21. Yamada K, Nabeshima T (2003) Brain-derived neurotrophic factor/TrkB signaling in memory processes. J Pharmacol Sci 91, 267-270.
22. Lee JL, Everitt BJ, Thomas KL (2004) Independent cellular processes for hippocampal memory consolidation and reconsolidation. Science 304, 839-843.
23. Reichardt LF (2006) Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 361, 1545-1564.
24. Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, Meyers VE, Coleman PD (2003) Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis 12, 97-109.
25. Onyango I, Khan S, Miller B, Swerdlow R, Trimmer P, Bennett P Jr (2006) Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer's disease. J Alzheimers Dis 9, 183-193. (Pubitemid 44078644)
26. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7, 695-702.
27. Connor B, Young D, Yan Q, Faull RLM, Synek B, Dragunow M (1997) Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Mol Brain Res 49, 71-81.
28. Salehi A, Verhaagen J, Dijkhuizen PA, Swaab DF (1996) Colocalization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience 75, 373-387.
29. Allen SJ, Wilcock GK, Dawbarn D (1999) Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochem Biophys Res Commun 264, 648-651.
30. Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, Wilson JM, DiStefano LM, Nobrega JN (1992) Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 59, 776-779.
31. Wolozin BL, Pruchnicki A, Dickson DW, Davies P (1986) A neuronal antigen in the brains of Alzheimer patients. Science 232, 648-650.
32. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci, 3017-3023.
33. Manczak M, Park BS, Jung Y, Reddy PH (2004) Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med 5, 147-162.
34. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83, 4913-4917.
35. Chun W, Johnson GV (2007) The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci 12, 733-756.
36. Fend F, Emmert-Buck MR, Chaqui R, Cole K, Lee J, Liotta LA, Ratfeld M (1999) Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am J Pathol 154, 61-66.
37. D'Andrea MR, Nagele RG, Wang H-Y, Peterson PA, Lee DH (2001) Evidence that neurons accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38, 120-134.
38. Luo L, Salunga RC, Guo H, Bittner A, Joy KC, Galindo JE, Xiao H, Rogers KE,Wan JS, Jackson MR, ErlanderMG(1999) Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med 5, 117-122.
39. D'Ippolito G, Diabira S, Howard GA, Menei P, Roos BA, Schiller PC (2004) Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 117, 2971-2981.
40. Garzon DJ, Fahnestock M (2007) Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci 27, 2628-2635.
41. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, e45.
42. Ramakers C, Ruijter JM, Deprez RM, Moorman AF (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339, 62-66.
43. Fujimura RK, Khamis I, Shapshak P, Goodkin K (2004) Regional quantitative comparison of multispliced to unspliced ratios of HIV-1 RNA copy number in infected human brain. J NeuroAIDS 2, 45-60.
44. Schindowski K, Belarbi K, Búee L (2008) Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 7, 43-56.
45. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
46. Tong L, Balazs R, Thornton PL, Cotman CW (2004) Betaamyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci 24, 6799-6809.
47. Elliott E, Atlas R, Lange A, Ginzburg I (2005) Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3Kinase signaling mechanism. Eur J Neurosci 22, 1081-1089.
48. Duyckaerts C, Potier M-C, Delatour B (2008) Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 115, 5-38.
49. Beglopoulos V, Shen J (2004) Gene-targeting technologies for the study of neurological disorders. Neuromolecular Med 6, 13-30.
50. Janus C (2008) Conditionally inducible tau mice - designing a better mouse model of neurodegenerative diseases. Genes Brain Behav 7 (Suppl 1), 12-27.
51. Nissen A, Mocanu M, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Zhou L, Rune G, Mandelkow E-M (2008) O4-01-02: Neurofibrillary tangles and neuronal loss in an inducible transgenic mouse model expressing a mutant repeat domain of tau. Alzheimers and Dement 4 (Suppl), T183-T184.
52. Castellani RJ, Zhu X, Lee HG, Smith MA, Perry G (2009) Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches. Int J Mol Sci 10, 1386-1406.